Deal Watch: Pfizer Circles Allergan, Which Continues Its Own M&A
Executive Summary
Allergan remains active, acquiring EU rights to Ironwood's linaclotide from Spain's Almirall. Novartis adds to its immuno-oncology pipeline with Admune purchase, it third I-O transaction in the past month.
You may also be interested in...
Valeant To Buy Dendreon’s Never-Was Cancer Vaccine Provenge
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.